Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-11

Hi Stayso,

I've been a holder in Graeme Kelly cancer therapy companies since 1998, including being a foundation holder of NOX and KZA (then NRT). A key reason for me buying into NOX was the success of our founder in curing himself from advanced prostate cancer through an abscopal response. So no, I don't agree at all that my hope was unrealistic, based on the evidence. 

Yes, the company is peddling a more conservative line these days. And I agree, as I said previously, that a drug which stops, and perhaps partially ameliorates the cancer (e.g. reduction of pain and/or tumour mass), would still be of considerable value. But it will not achieve the same degree or rapidity of commercial success compared with a treatment which frequently achieves full abscopal responses. Any drug which could frequently repeat what happened to Dr Kelly would get the red carpet laid out to expedite its progress to commercialisation. But I no longer have much hope of that happening. Never mind, I've had 21 years of practice at being patient, so I'm quite good at it by now! 

Longer term upside - treating early stage patients in combination with conventional anti-tumour drugs could prove extremely effective - the conventional drug attaching the tumour, Veyonda dealing with the stem cells and preventing recurrence.

And I still applaud Dr Kelly's diligence in exploring a variety of avenues with this drug to find a quick and cost effective route to commercialisation.